Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Sebastian Debus

Showing results (71-80 of 104) with videos related to

Pageof 11
Sort By:
VASA. Zeitschrift Fur Gefasskrankheiten|August 19, 2020
Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease - a health insurance claims data analysisMark Kaschwich, Frederik Peters, Sandra Hischke, et al.
Clinical Cardiology|October 17, 2022
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PADMarc P Bonaca, Michael Szarek, E Sebastian Debus, et al.
Scientific Reports|April 29, 2021
The use of pulse pressure variation for predicting impairment of microcirculatory blood flowChristoph R Behem, Michael F Graessler, Till Friedheim, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|April 5, 2021
Reply to "The VOYAGER PAD Trial in Surgical Perspective: A Debate"E Sebastian Debus, Mark Nehler, , et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 20, 2022
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA RegistryKeith A A Fox, Victor Aboyans, E Sebastian Debus, et al.
Atherosclerosis|November 29, 2025
Heparin decreases serum sphingosine-1-phosphate levels in patients with vascular diseasesYi Qin, Yu Jiang, Mirjam von Lucadou, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|October 23, 2021
Editor's Choice - Update of the European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia in Light of the COVID-19 Pandemic, Based on a Scoping Review of the LiteratureVincent Jongkind, Jonothan J Earnshaw, Frederico Bastos Gonçalves, et al.
Atherosclerosis Plus|January 16, 2023
Differential association of flow velocities in the carotid artery with plaques, intima media thickness and cardiac functionDavid Leander Rimmele, Katrin Borof, Jan-Per Wenzel, et al.
Circulation|October 18, 2023
Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PADJennifer Rymer, Sonia S Anand, E Sebastian Debus, et al.
Journal of the American Heart Association|October 23, 2025
Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PADShea Hogan, Michael Szarek, E Sebastian Debus, et al.
Pageof 11

Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
VASA. Zeitschrift Fur Gefasskrankheiten|August 19, 2020
Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease - a health insurance claims data analysisMark Kaschwich, Frederik Peters, Sandra Hischke, et al.
Clinical Cardiology|October 17, 2022
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PADMarc P Bonaca, Michael Szarek, E Sebastian Debus, et al.
Scientific Reports|April 29, 2021
The use of pulse pressure variation for predicting impairment of microcirculatory blood flowChristoph R Behem, Michael F Graessler, Till Friedheim, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|April 5, 2021
Reply to "The VOYAGER PAD Trial in Surgical Perspective: A Debate"E Sebastian Debus, Mark Nehler, , et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 20, 2022
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA RegistryKeith A A Fox, Victor Aboyans, E Sebastian Debus, et al.
Atherosclerosis|November 29, 2025
Heparin decreases serum sphingosine-1-phosphate levels in patients with vascular diseasesYi Qin, Yu Jiang, Mirjam von Lucadou, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|October 23, 2021
Editor's Choice - Update of the European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia in Light of the COVID-19 Pandemic, Based on a Scoping Review of the LiteratureVincent Jongkind, Jonothan J Earnshaw, Frederico Bastos Gonçalves, et al.
Atherosclerosis Plus|January 16, 2023
Differential association of flow velocities in the carotid artery with plaques, intima media thickness and cardiac functionDavid Leander Rimmele, Katrin Borof, Jan-Per Wenzel, et al.
Circulation|October 18, 2023
Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PADJennifer Rymer, Sonia S Anand, E Sebastian Debus, et al.
Journal of the American Heart Association|October 23, 2025
Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PADShea Hogan, Michael Szarek, E Sebastian Debus, et al.
Pageof 11